Ketorolac/phenylephrine - Rayner
Alternative Names: Omidria; OMS-302; OMS-302-PE; Phenylephrine and ketorolac intraocular solution; Phenylephrine/ketorolacLatest Information Update: 06 Feb 2024
Price :
$50 *
At a glance
- Originator Omeros Corporation
- Class Analgesics; Anti-inflammatories; Antihypotensives; Decongestants; Ethanolamines; Eye disorder therapies; Indoles; Mydriatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Urologics
- Mechanism of Action Alpha 1 adrenergic receptor agonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Miosis; Postoperative pain
Most Recent Events
- 02 Dec 2021 Rayner acquires ketorolac/phenylephrine and related business assets from Omeros Corporation
- 24 May 2018 Omeros Corporation enters into a settlement agreement with Lupin and its subsidiary Lupin Pharmaceuticals, resolving Omeros’ patent litigation against Lupin's filing of an ANDA seeking approval from the US FDA to market a generic version of ketorolac/phenylephrine
- 12 Dec 2017 Registered for Miosis (In adolescents, In children, In infants, In neonates, Prevention) in USA (Intraocular)